What does Everest Organics do?

Everest Organics Ltd manufactures Active Pharmaceutical Ingredients and intermediaries in the Pharmaceuticals & Biotechnology sector. As of March 2025, it reported net sales of 41 Cr and a net profit of 3 Cr, with a market cap of Rs 409 Cr.

Overview: <BR>Everest Organics Ltd is engaged in the manufacturing of Active Pharmaceutical Ingredients and their intermediaries within the Pharmaceuticals & Biotechnology industry, categorized as a Micro Cap company.<BR><BR>History: <BR>Incorporated in February 1993, Everest Organics commenced its commercial operations in the same year. The company reported its latest quarterly results for March 2025, showing net sales and profit figures.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 41 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 3 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 409 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 1.25 <BR>Return on Equity: -3.19% <BR>Price to Book: 10.00<BR><BR>Contact Details: <BR>Address: Aroor Village, Sadasivpet Mandal Medak Telangana : 502291 <BR>Tel: 91-8455-250113 <BR>Email: srihari_everest@rediffmail.com <BR>Website: http://www.everestorganicsltd.com

Who are in the management team of Everest Organics?

As of March 2023, the management team of Everest Organics includes S K Hari Krishna (Whole-time Director), A Parvatisem (Director - Technical), K. Ramakrishnam Raju (Chairman & Independent Director), Raju S Kakarlapudi (Non-Executive Director), Srikakarlapudi Sirisha (Managing Director & CEO), Venkatasatyanarayana Murthy Chayaly (Independent Director), Abdur Rahman (Company Secretary & Compliance Officer), and Sundara Prasad Venkata Satya Srikakolapu (Independent Director). This team oversees the company's strategic direction and management.

As of March 2023, the management team of Everest Organics includes the following individuals:<BR><BR>1. S K Hari Krishna - Whole-time Director<BR>2. A Parvatisem - Director (Technical)<BR>3. K. Ramakrishnam Raju - Chairman & Independent Director<BR>4. Raju S Kakarlapudi - Non Executive Director<BR>5. Srikakarlapudi Sirisha - Managing Director & CEO<BR>6. Venkatasatyanarayana Murthy Chayaly - Independent Director<BR>7. Abdur Rahman - Company Secretary & Compliance Officer<BR>8. Sundara Prasad Venkata Satya Srikakolapu - Independent Director<BR><BR>This team is responsible for the strategic direction and management of the company.

Has Everest Organics declared dividend?

Everest Organics Ltd has declared a 5% dividend, amounting to 0.5 per share, with an ex-date of September 15, 2022. Despite the dividend declaration, the yield remains at 0%, as the company's strong price returns have driven total returns across various periods.

Everest Organics Ltd has declared a 5% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 5%<BR>- Amount per share: 0.5<BR>- Ex-date: 15 Sep 22<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was 190.1%, with a dividend return of 0%, resulting in a total return of 190.1%.<BR><BR>For the 1-year period, the price return was 249.94%, with a dividend return of 0%, leading to a total return of 249.94%.<BR><BR>Over the 2-year period, the price return was 325.04%, and the dividend return was 0%, culminating in a total return of 325.04%.<BR><BR>In the 3-year period, the price return was 182.86%, with a dividend return of 0.38%, resulting in a total return of 183.24%.<BR><BR>For the 4-year period, the price return was 15.24%, with a dividend return of 0.44%, leading to a total return of 15.68%.<BR><BR>In the 5-year period, the price return was 223.93%, with a dividend return of 1.72%, culminating in a total return of 225.65%.<BR><BR>Overall, while Everest Organics has declared a dividend, the dividend yield remains at 0%, indicating that the dividends have not significantly contributed to the total returns. However, the company has shown strong price returns across all periods, suggesting robust performance in its stock value.

Who are the peers of the Everest Organics?

Everest Organics' peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, SMS Lifesciences, Zenotech Lab, Oxygenta Pharma, and Fredun Pharma. Everest Organics has the highest 1-year return at 252.60%, while Fredun Pharma has the lowest at -8.48%.

Peers: The peers of Everest Organics are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, SMS Lifesciences, Zenotech Lab., Oxygenta Pharma, and Fredun Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Good management risk is found at Divi's Lab., Torrent Pharma, and the rest. Average management risk is present at Everest Organics, SMS Lifesciences, Zenotech Lab., and Fredun Pharma. For growth, Excellent growth is seen at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is noted at Divi's Lab., Torrent Pharma, Everest Organics, SMS Lifesciences, Zenotech Lab., and the rest. Capital Structure is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, Good for Torrent Pharma, Average for SMS Lifesciences, and Below Average for Everest Organics and Fredun Pharma.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Everest Organics at 252.60%, while the peer with the lowest is Fredun Pharma at -8.48%. Everest Organics' return significantly exceeds all its peers. Additionally, SMS Lifesciences and Zenotech Lab. have negative six-month returns.

What is the technical trend for Everest Organics?

As of April 3, 2025, Everest Organics shows a bullish trend supported by positive MACD and moving averages, but caution is advised due to bearish RSI readings indicating potential momentum weakness.

As of 3 April 2025, the technical trend for Everest Organics has changed from mildly bullish to bullish. The weekly and monthly MACD indicators are both bullish, supporting the positive trend. Daily moving averages also indicate a bullish stance. However, the RSI readings are bearish on both weekly and monthly time frames, suggesting some weakness in momentum. The Bollinger Bands are mildly bullish on both time frames, indicating potential for upward movement. Overall, the current stance is bullish, but the bearish RSI signals indicate caution regarding the strength of this trend.

Who are the top shareholders of the Everest Organics?

The top shareholders of Everest Organics include Veerat Finance Investment Limited with 38.37%, followed by Greenpath Energy Private Limited at 8.47%, and individual investors holding 23.87%. There are no pledged promoter holdings, mutual funds, or foreign institutional investors involved.

The top shareholders of Everest Organics include the promoters, with Veerat Finance Investment Limited holding the largest stake at 38.37%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors (FIIs) holding shares. The highest public shareholder is Greenpath Energy Private Limited, which owns 8.47%. Additionally, individual investors collectively hold 23.87% of the shares.

How big is Everest Organics?

As of 24th July, Everest Organics Ltd has a market capitalization of 337.00 Cr and reported net sales of 159.48 Cr with a net loss of 1.29 Cr over the latest four quarters. Shareholder's funds were 45.84 Cr and total assets were 226.72 Cr as of March 2024.

As of 24th July, Everest Organics Ltd has a market capitalization of 337.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Everest Organics reported net sales of 159.48 Cr. However, the company experienced a loss of 1.29 Cr in net profit during the same period.<BR><BR>The latest annual period for the balance sheet is March 2024, where shareholder's funds amounted to 45.84 Cr and total assets were reported at 226.72 Cr.

When is the next results date for Everest Organics?

The next results date for Everest Organics is 05 August 2025.

The next results date for Everest Organics is scheduled for 05 August 2025.

Are Everest Organics latest results good or bad?

Everest Organics reported strong financial results for the quarter ending June 2025, with Profit After Tax increasing by 537.2% to Rs 1.41 crore and net sales rising 35.0% to Rs 53.81 crore, indicating a positive performance and significant growth in profitability. Despite a decline in standalone net profit growth from the previous quarter, the overall metrics reflect a robust recovery in the pharmaceutical sector, making the results good.

Everest Organics has reported strong financial results for the quarter ending June 2025, indicating a positive performance overall. The company achieved a significant turnaround, with Profit After Tax (PAT) soaring to Rs 1.41 crore, a remarkable growth of 537.2% compared to the previous average PAT. This suggests that the company has improved its profitability significantly.<BR><BR>Net sales also saw a substantial increase, reaching Rs 53.81 crore, which is a 35.0% rise from the average of the prior four quarters. Additionally, the operating profit (PBDIT) reached Rs 4.44 crore, marking the highest level in the last five quarters. The operating profit to interest ratio improved to a record high of 3.39 times, showcasing better management of interest payments.<BR><BR>While there was a decline in standalone net profit growth compared to the previous quarter, the overall financial metrics reflect a robust performance and a positive trajectory for the company. The overall score for Everest Organics improved significantly, further indicating its strong performance in the market. Thus, the latest results can be considered good, highlighting the company's growth and recovery in the pharmaceutical sector.

How has been the historical performance of Everest Organics?

Everest Organics has experienced a decline in financial performance, with net sales dropping from 197.24 Cr in March 2024 to 159.48 Cr in March 2025, resulting in negative profits and cash flow challenges. The company's operating profit decreased significantly, reflecting volatility and reduced profitability in the latest fiscal year.

Answer:<BR>The historical performance of Everest Organics shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Everest Organics reported net sales of 159.48 Cr in March 2025, a decline from 197.24 Cr in March 2024 and 183.05 Cr in March 2023, indicating a downward trend in revenue. The total operating income mirrored this decline, falling to 159.48 Cr in March 2025 from 197.24 Cr in the previous year. Raw material costs decreased to 97.50 Cr in March 2025 from 123.41 Cr in March 2024, contributing to a total expenditure of 152.26 Cr, down from 186.25 Cr. Operating profit, excluding other income, was 7.22 Cr in March 2025, a decrease from 10.99 Cr in March 2024, leading to a profit before tax of -3.24 Cr in March 2025, compared to a profit of 0.61 Cr in March 2024. The profit after tax also turned negative at -1.29 Cr in March 2025, following a profit of 0.14 Cr in March 2024. The company's equity capital increased to 9.71 Cr in March 2025 from 8.00 Cr in March 2024, while total liabilities slightly decreased to 224.48 Cr from 226.62 Cr. Cash flow from operating activities was negative at -5.00 Cr in March 2025, contrasting with a positive cash flow of 16.00 Cr in March 2024, reflecting challenges in cash generation. Overall, the financial performance of Everest Organics indicates significant volatility and a decline in profitability in the most recent fiscal year.

Should I buy, sell or hold Everest Organics?

Which are the latest news on Everest Organics?

Why is Everest Organics falling/rising?

As of 04-Dec, Everest Organics Ltd's stock price is currently 418.90, reflecting a 0.6% increase. The stock has shown strong performance with a year-to-date rise of 39.15%, outperforming the Sensex and indicating positive investor sentiment despite a recent decline in delivery volume.

As of 04-Dec, Everest Organics Ltd's stock price is rising, currently at 418.90, reflecting a change of 2.5 (0.6%) upward. The stock has shown strong performance over various periods, with a year-to-date increase of 39.15% compared to the Sensex's 9.12%. Additionally, in the last month, the stock has risen by 8.35%, while the Sensex has only increased by 2.16%. <BR><BR>Today, the stock has outperformed its sector by 0.31% and has been on a consecutive gain streak for the last two days, accumulating a total return of 1.32% during this period. Furthermore, Everest Organics is trading above its moving averages across multiple time frames, indicating a positive trend. Despite a recent decline in delivery volume, which fell by 57.55% against the 5-day average, the overall upward momentum in stock price and performance relative to the benchmark suggests that investor sentiment remains favorable, contributing to the rise in stock price.

Is Everest Organics overvalued or undervalued?

As of December 4, 2025, Everest Organics is considered overvalued with a high PE ratio of 61.45 and other premium valuation metrics compared to its peers, indicating limited upside potential despite strong recent stock performance.

As of 4 December 2025, Everest Organics has moved from a fair to an expensive valuation grade. The company is currently considered overvalued based on its high PE ratio of 61.45, an EV to EBIT of 41.56, and a Price to Book Value of 5.61. These ratios indicate that the stock is trading at a premium compared to its earnings and book value, suggesting limited upside potential relative to its current price.<BR><BR>In comparison to its peers, Everest Organics' valuation stands out as significantly higher; for instance, Sun Pharma has a PE of 37.78 and an EV to EBITDA of 24.99, while Cipla, which is rated attractive, has a PE of 22.58 and an EV to EBITDA of 15.98. This stark contrast highlights Everest Organics' overvaluation in the context of the industry. Despite its strong recent stock performance, with a year-to-date return of 39.15% compared to the Sensex's 9.12%, the underlying valuation metrics suggest that investors may be overestimating the company's growth prospects.